Screener
Kymera Therapeutics KYMR Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Marketable securities (Note 4) | 566,508 | 491,265 |
| Accounts receivable | 20,000 | — |
| Prepaid expenses and other current assets | 26,280 | 22,938 |
| Total current assets | $737,265 | $871,214 |
| Marketable securities, non-current (Note 4) | 813,901 | 771,158 |
| Property and equipment, net (Note 6) | 39,971 | 43,175 |
| Right-of-use assets, operating leases | 41,100 | 42,351 |
| Other non-current assets | 7,385 | 9,114 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's total current assets?
- Kymera Therapeutics (KYMR) reported total current assets of $737.27M in Q2 2026.
- How has Kymera Therapeutics's total current assets changed year-over-year?
- Kymera Therapeutics's total current assets increased by 1.2% year-over-year, from $728.33M to $737.27M.
- What is the long-term trend for Kymera Therapeutics's total current assets?
- Over 5 years (2020 to 2025), Kymera Therapeutics's total current assets has grown at a 23.6% compound annual growth rate (CAGR), from $302.34M to $871.21M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Kymera Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude